Clearpoint Neuro Inc (OQ:CLPT)

Business Focus: Advanced Medical Equipment & Technology

Get the company report for the most recent outlook updated daily

Apr 24, 2024 04:05 pm ET

ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has initiated the Limited Market Release for its SmartFrame OR™...

Apr 23, 2024 04:05 pm ET

ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on...

Apr 16, 2024 04:05 pm ET

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the...

Apr 08, 2024 09:15 am ET

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)

NEW YORK, April 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The investigation seeks to determine whether ClearPoint Neuro's directors breached their fiduciary duties in connection with recent corporate actions.

Mar 19, 2024 08:07 am ET

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Mar 12, 2024 04:05 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended...

Mar 11, 2024 08:00 am ET

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that preclinical results of an in vivo validation study have been...

Mar 01, 2024 04:05 pm ET

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter...

Feb 29, 2024 08:00 am ET

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares...

Feb 28, 2024 04:45 pm ET

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its...

Feb 21, 2024 04:05 pm ET

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced FDA Clearance and first-in-human cases using the ClearPoint 2.2...

Jan 24, 2024 04:05 pm ET

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced installation and completion of an initial procedure with both the...

Jan 22, 2024 04:05 pm ET

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) clearance for...

Jan 16, 2024 08:00 am ET

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its SmartFrame OR™ Stereotactic...

Jan 08, 2024 04:05 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter and full year ended...

Nov 09, 2023 04:05 pm ET

ClearPoint Neuro Reports Third Quarter 2023 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter...

Oct 26, 2023 04:05 pm ET

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 third quarter on Thursday,...

Aug 08, 2023 04:05 pm ET

ClearPoint Neuro Reports Second Quarter 2023 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter...

Jul 25, 2023 04:05 pm ET

ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

May 24, 2023 09:25 am ET

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global...

May 18, 2023 04:01 pm ET

ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities 2023 Institutional...

May 11, 2023 04:05 pm ET

ClearPoint Neuro Reports First Quarter 2023 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter...

May 10, 2023 04:05 pm ET

ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 26th American Society of...

Apr 28, 2023 04:42 pm ET

ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

Apr 20, 2023 04:05 pm ET

ClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023: ClearPoint Maestro® Brain Model and ClearPoint Prism™ Neuro Laser Therapy System

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will exhibit at the 2023 American Association of Neurological Surgeons (AANS)...

Apr 18, 2023 04:05 pm ET

ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive worldwide agreement with NE Scientific, LLC, a leader in biophysics...

Apr 13, 2023 04:05 pm ET

ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced successful registration of its Neuro Navigation portfolio with the Brazilian...

Apr 11, 2023 04:05 pm ET

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced further expansion of its worldwide license and research agreement with Philips, a...

Mar 28, 2023 04:05 pm ET

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San...

Mar 01, 2023 04:05 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2022. 2022...

Feb 15, 2023 04:05 pm ET

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 fourth quarter and full year on...

Jan 11, 2023 08:00 am ET

ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue

Dec 12, 2022 09:15 am ET

ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Sweden

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced enrollment of the first patient in a Glioblastoma clinical trial using the ClearPoint...

Nov 09, 2022 09:25 am ET

ClearPoint Neuro to Present at Upcoming Investor Conferences

Nov 08, 2022 04:05 pm ET

ClearPoint Neuro Reports Third Quarter 2022 Results

Oct 26, 2022 04:05 pm ET

ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022

Sep 23, 2022 02:45 am ET

ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k)...

Sep 20, 2022 04:05 pm ET

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating...

Sep 19, 2022 04:13 pm ET

ClearPoint Neuro Announces FDA Clearance for Software Version 2.1

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of the ClearPoint Neuro...

Aug 09, 2022 04:15 pm ET

ClearPoint Neuro Reports Second Quarter 2022 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022. Second Quarter...

Aug 09, 2022 04:05 pm ET

ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has received 510(k) clearance for its ClearPoint Maestro™ Brain Model. Maestro is...

Aug 08, 2022 04:05 pm ET

ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory...

Jul 26, 2022 04:05 pm ET

ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022

Jul 21, 2022 04:20 pm ET

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted marketing authorization for Upstaza™...

Jun 29, 2022 04:05 pm ET

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patient in their Phase 1/2...

Jun 02, 2022 04:05 pm ET

ClearPoint Neuro Announces Receipt of MDSAP Certification

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the receipt of certification for the Medical Device Single Audit Program (MDSAP)....

May 20, 2022 09:29 am ET

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner PTC Therapeutics for receiving a positive opinion from the European...

May 13, 2022 09:25 am ET

ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 25th Annual Meeting of the...

May 11, 2022 04:05 pm ET

ClearPoint Neuro Reports First Quarter 2022 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2022. First Quarter...

May 03, 2022 04:05 pm ET

ClearPoint Neuro and Higgs Boson Health Announce Collaboration

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a collaboration with Higgs Boson Health (Durham, NC) to bring to market a...

Apr 28, 2022 04:05 pm ET

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has received FDA clearance for version 1.1 of its next generation SmartFrame...

Apr 27, 2022 04:05 pm ET

ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced expansion of their worldwide license and research agreement with Philips, a global...

Apr 26, 2022 04:05 pm ET

ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022

Mar 29, 2022 04:01 pm ET

ClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference

Mar 01, 2022 04:07 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2021. 2021...

Feb 15, 2022 04:05 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue

Jan 05, 2022 04:05 pm ET

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BIOCONNECT Virtual...

Nov 17, 2021 04:05 pm ET

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the...

Nov 09, 2021 04:05 pm ET

ClearPoint Neuro Reports Third Quarter 2021 Results

Nov 08, 2021 04:05 pm ET

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration...

Nov 04, 2021 04:05 pm ET

ClearPoint Neuro to Present at the 2021 Stifel Virtual Healthcare Conference

Nov 02, 2021 04:05 pm ET

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of...

Oct 26, 2021 04:05 pm ET

ClearPoint Neuro to Announce Third Quarter 2021 Results November 9, 2021

Aug 10, 2021 04:05 pm ET

ClearPoint Neuro Reports Second Quarter 2021 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2021. Second Quarter...

Aug 09, 2021 08:00 am ET

ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has entered into a strategic and commercial partnership with German-based surgical equipment leader...

Aug 04, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® Neuro Navigation System at Hôpital Fondation Rothschild in Paris

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its ClearPoint Neuro Navigation System at Hôpital Fondation Rothschild in Paris,...

Aug 02, 2021 04:05 pm ET

ClearPoint Neuro to Announce Second Quarter 2021 Results August 10, 2021

Jul 21, 2021 04:05 pm ET

Blackrock Neurotech, ClearPoint Neuro to Address Neurological Disorders With Novel Brain-Computer Interface Surgical Solution

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a joint agreement with Blackrock Neurotech to develop an automated surgical solution...

Jul 15, 2021 04:30 pm ET

ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company’s Board of Directors...

Jun 16, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland. “We...

Jun 14, 2021 09:15 am ET

ClearPoint Neuro Set to Join Russell 3000® Index

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes...

Jun 08, 2021 07:30 am ET

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned...

May 19, 2021 04:05 pm ET

ClearPoint Neuro to Present at the UBS Global Healthcare Virtual Conference

May 18, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today announced the first human cases of the SmartFrame Array Neuro Navigation System and Software. The ‘Array’...

May 11, 2021 04:05 pm ET

ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2021. First Quarter...

May 10, 2021 05:21 pm ET

ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a partnership with San Diego-based D&K Engineering for the continued development of a...

Apr 29, 2021 04:38 pm ET

ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021

Apr 28, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates Voyager Therapeutics on receiving FDA clearance of the IND application for their...

Apr 23, 2021 05:00 pm ET

ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that on September 14, 2020, the Company’s Board of Directors approved the grant to Mr....

Apr 13, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Board of Directors. Mr....

Apr 06, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in the first dose...

Mar 24, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms....

Mar 04, 2021 04:05 pm ET

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2020. 2020...

Feb 23, 2021 04:05 pm ET

ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common stock. The total...

Feb 19, 2021 04:05 pm ET

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021

Feb 18, 2021 10:10 pm ET

ClearPoint Neuro Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the pricing of its underwritten public offering of 1,850,140 shares of its common...

Feb 18, 2021 04:35 pm ET

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the commencement of a proposed underwritten public offering of its shares of common...

Feb 18, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a worldwide license and research agreement with Philips, a global leader in health...

Feb 11, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a multi-product joint development and option agreement with Blackrock Microsystems...

Feb 05, 2021 08:00 am ET

ClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company’s Board of Directors. The prior Chairman, Kimble L. Jenkins, retired from the Chairman role, which he has held...

Jan 26, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and...

Jan 14, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro...

Jan 12, 2021 04:05 pm ET

ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported preliminary unaudited revenue results for the quarter and full year ended December 31,...

Dec 29, 2020 04:15 pm ET

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financing agreement with...

Nov 30, 2020 09:15 am ET

ClearPoint Neuro Completes 4,000th ClearPoint® Neuro Navigation Procedure

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided stereotactic neurosurgery, announced that its 4,000th neurosurgical procedure using the ClearPoint Neuro Navigation System was completed earlier this month at Dartmouth-Hitchcock...

Nov 10, 2020 04:05 pm ET

ClearPoint Neuro Reports Third Quarter 2020 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, today announced financial results for its third fiscal quarter ended September 30, 2020. Third...

Nov 04, 2020 04:05 pm ET

ClearPoint Neuro to Announce Third Quarter 2020 Results on November 10

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 third quarter, which ended September 30, 2020, on Tuesday, November 10, 2020 after the market close. The Company will...

Sep 14, 2020 04:15 pm ET

ClearPoint Neuro Announces Transition Plan for New Chief Financial Officer

ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that global medical device financial executive Danilo D’Alessandro has been appointed the Company’s next Chief Financial Officer (CFO) succeeding Harold A. (Hal) Hurwitz who plans to...

Aug 12, 2020 04:05 pm ET

ClearPoint Neuro Reports Second Quarter 2020 Results

ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its second fiscal quarter and six months ended June 30, 2020. Financial Results – Three Months Ended June 30, 2020 Total revenues for the quarter were...

Aug 06, 2020 08:00 am ET

ClearPoint Neuro to Announce Second Quarter 2020 Results on August 12

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 second quarter, which ended June 30, 2020, on Wednesday, August 12, 2020 after the market close. The Company will subsequently...

May 12, 2020 04:05 pm ET

Ad blocking detected

Clearpoint Neuro Inc (OQ:CLPT)

Business Focus: Advanced Medical Equipment & Technology